Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
Mo | ProKidney boosts leadership for phase 3 program clinical program | 1 | Investing.com | ||
Mo | ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations | 73 | GlobeNewswire (Europe) | Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies Mr. Lucio Tozzi joined in... ► Artikel lesen | |
22.03. | PROKIDNEY CORP. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
22.03. | ProKidney GAAP EPS of -$0.57 beats by $0.08 | 1 | Seeking Alpha | ||
22.03. | ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights | 99 | GlobeNewswire (Europe) | WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic... ► Artikel lesen | |
07.03. | Morgan Stanley starts ProKidney stock coverage, focus on new therapy 'REACT' | 2 | Investing.com | ||
12.02. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
19.01. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
30.11.23 | PROKIDNEY CORP. - 8-K, Current Report | - | SEC Filings | ||
30.11.23 | ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer | 1 | GlobeNewswire (USA) | ||
21.11.23 | ProKidney former 10% owner Chamath Palihapitiya discloses sale of over 7M shares | 1 | Seeking Alpha | ||
21.11.23 | ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference | 1 | GlobeNewswire (USA) | ||
17.11.23 | ProKidney Corp. (PROK) Q3 2023 Earnings Call Transcript | 1 | Insider Monkey | ||
14.11.23 | ProKidney amends Phase III protocol in light of Phase II results | 3 | Pharmaceutical Technology | ||
14.11.23 | ProKidney reports higher Q3 loss, strong cash position | 1 | Investing.com | ||
14.11.23 | ProKidney GAAP EPS of -$0.18 | 1 | Seeking Alpha | ||
14.11.23 | ProKidney Reports Third Quarter Financial Results | 211 | GlobeNewswire (Europe) | WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD)... ► Artikel lesen | |
14.11.23 | ProKidney appoints new CEO, updates Phase 3 plans for REACT therapy | 1 | Seeking Alpha | ||
13.11.23 | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EPIGENOMICS | 1,860 | -0,80 % | EQS-News: Epigenomics AG veröffentlicht Finanzergebnisse für das Geschäftsjahr 2023 | EQS-News: Epigenomics AG
/ Schlagwort(e): Jahresergebnis/Jahresbericht
Epigenomics AG veröffentlicht Finanzergebnisse für das Geschäftsjahr 2023
14.03.2024 / 08:00 CET/CEST
Für... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 1,185 | +0,85 % | Raus aus BioNTech und rein in Defence Therapeutics und Evotec Aktie? | Bei der BioNTech-Aktie ist derzeit die Luft raus. Obwohl sich die Stimmung im Sektor verbessert, so ist Star-Investorin Cathie Wood kürzlich bei Moderna eingestiegen, kommt der deutsche Biotech-Primus... ► Artikel lesen | |
GINKGO BIOWORKS | 1,180 | 0,00 % | AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production | ||
BEAM THERAPEUTICS | 33,060 | -2,65 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
ONCOLYTICS BIOTECH | 0,975 | +3,72 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights | Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX
Impressive objective response... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 9,990 | 0,00 % | Recursion Pharmaceuticals: Recursion Publishes Annual Environmental, Social and Governance Report | ||
ARCTURUS THERAPEUTICS | 33,550 | +2,10 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
ASSERTIO | 0,956 | -4,45 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
SIGA TECHNOLOGIES | 8,495 | 0,00 % | Dividendenbekanntmachungen (25.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABB LTD CH0012221716 0,999 USD 0,9242 EUR ABB LTD ADR US0003752047 0,9993 USD 0,9245 EUR ACADEMY SPORTS AND OUTDOORS INC US00402L1070 0... ► Artikel lesen | |
MERRIMACK PHARMACEUTICALS | 14,750 | 0,00 % | MERRIMACK PHARMACEUTICALS INC - 8-K, Current Report | ||
VIR BIOTECHNOLOGY | 10,115 | +0,15 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
BIO-PATH | 4,030 | -1,95 % | BIO-PATH HOLDINGS INC - 8-K, Current Report | ||
VERVE THERAPEUTICS | 13,340 | +1,14 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
ARS PHARMACEUTICALS | 10,300 | +3,41 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results | Preparing to submit response to the FDA's CRL for neffy® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen... ► Artikel lesen | |
ARVINAS | 41,100 | -0,56 % | Arvinas Inc.: Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer | NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen |